Successful control of recurrent MAS by canakinumab in a Sjögren syndrome patient with homozygous MEFV P369S variants and review of literatures
Modern Rheumatology Case Reports · 2025
DOI: 10.1093/mrcr/rxaf016 ↗Kurz gefasst
Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2025. Verfasst von Nobuyuki Ono und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Biosystem Science, Graduate School of Medical Science, Faculty of Medicine, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Macrophage Activation Syndrome, Pyrin. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Macrophage activation syndrome (MAS) is an autoinflammatory condition, which severely complicates autoimmune diseases, such as systemic juvenile idiopathic arthritis, adult onset Still’s disease, and systemic lupus erythematosus. MEFV gene encodes a component of pyrin inflammasome, whose variants cause familial Mediterranean fever (FMF). We experienced a recurrent MAS case with homozygous MEFV P369S variants accompanied by Sjögren syndrome and pulmonary arterial hypertension, whose recurrent MAS was successfully treated with canakinumab. Pathogenicity of MEFV P369S variant is still inconsistent, and clinical interpretation of this variant is challenging. Thus, we reviewed previous literatures and revealed that the majority of FMF patients with collagen diseases in carried MEFV P369S variant, all of which were reported from Japan. In this case-based review, we clarify the epidemiology of MEFV variants in collagen diseases and discuss the significance of their genetic analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Biosystem Science, Graduate School of Medical Science, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
- Department of Rheumatology, Fukuoka City Hospital, Fukuoka, Japan.
- Department of Clinical Immunology and Rheumatology/Infectious Disease, Kyushu University Hospital, Fukuoka, Japan.
- Department of Rheumatology, Iizuka Hospital Iizuka Hospital, Fukuoka, Japan.
- Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan.
- Department of Dermatology, Kyushu University Hospital, Fukuoka, Japan.
ORCID-Profile: Nobuyuki Ono, Hiroaki Niiro
Zitieren
APA
Ono, N., Yoshimura, M., Nishida, T., Yamauchi, Y., Doi, G., Fuyuno, Y., Sonoda, M., & Niiro, H. (2025). Successful control of recurrent MAS by canakinumab in a Sjögren syndrome patient with homozygous MEFV P369S variants and review of literatures. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxaf016
Vancouver
Ono N, Yoshimura M, Nishida T, Yamauchi Y, Doi G, Fuyuno Y, et al. Successful control of recurrent MAS by canakinumab in a Sjögren syndrome patient with homozygous MEFV P369S variants and review of literatures. Modern Rheumatology Case Reports. 2025. doi:10.1093/mrcr/rxaf016
BibTeX
@article{Ono2025,
author = {Ono, Nobuyuki and Yoshimura, Motoki and Nishida, Toshiya and Yamauchi, Yusuke and Doi, Goro and Fuyuno, Yoko and Sonoda, Motoshi and Niiro, Hiroaki},
title = {Successful control of recurrent MAS by canakinumab in a Sjögren syndrome patient with homozygous MEFV P369S variants and review of literatures},
journal = {Modern Rheumatology Case Reports},
year = {2025},
doi = {10.1093/mrcr/rxaf016}
}
EUVIMED